Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM

Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines

A multidisciplinary team approach to cancer care in the Philippines

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC

Neo-adjuvant therapy for different cancers in the Philippines

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity